In pediatric patients with impetigo, is cefalexin or co‑amoxiclav the preferred oral therapy?

Cephalexin is the preferred oral antibiotic for pediatric impetigo

For pediatric patients with impetigo, cephalexin is the better choice over co-amoxiclav based on current guideline recommendations and clinical evidence demonstrating superior efficacy.

Guideline-Based Recommendation

The 2014 IDSA guidelines for skin and soft tissue infections explicitly list both agents as acceptable options for impetigo treatment in children 1. However, the dosing and positioning differ:

• Cephalexin: 25–50 mg/kg/day divided into 3–4 doses
• Amoxicillin-clavulanate (co-amoxiclav): 25 mg/kg/day of the amoxicillin component divided into 2 doses

Both target the primary pathogens (Staphylococcus aureus and Streptococcus pyogenes) that cause impetigo 1.

Clinical Evidence Supporting Cephalexin

A pivotal 1990 comparative trial directly addressed this question 2. In 73 children with impetigo:

• Cephalexin: 0% treatment failure rate (0/25 patients)
• Erythromycin: 4% treatment failure rate (1/25 patients)
• Penicillin V: 24% treatment failure rate (6/25 patients)

The study found S. aureus was the causative organism in 81% of cases (either alone or with streptococci), making cephalexin's excellent anti-staphylococcal coverage particularly relevant 2.

Why Cephalexin Over Co-Amoxiclav

Efficacy Profile

While a 1996 study showed co-amoxiclav achieved 96% cure rates in severe pyoderma 3, this was not significantly superior to amoxicillin alone (90%), suggesting the clavulanic acid component adds limited benefit in typical community-acquired impetigo where beta-lactamase-producing organisms are less prevalent.

Tolerability Considerations

Co-amoxiclav causes more gastrointestinal side effects than cephalosporins 3. The FDA labeling for cephalexin notes it is "substantially excreted by the kidney" with established safety in pediatric populations 4. The broader spectrum of co-amoxiclav may unnecessarily increase antibiotic resistance pressure.

Dosing Convenience

Cephalexin requires 3–4 daily doses versus co-amoxiclav's twice-daily dosing. However, the superior efficacy data for cephalexin outweighs this minor inconvenience 1, 2.

Clinical Algorithm

For mild-to-moderate impetigo (limited lesions):

• Start with topical mupirocin 2% or retapamulin 1% applied twice daily 5, 6

For extensive/severe impetigo or outbreak settings:

1. First-line: Cephalexin 25–50 mg/kg/day divided into 3–4 doses for 10 days 1, 2
2. Alternative: Co-amoxiclav 25 mg/kg/day (amoxicillin component) divided twice daily if cephalexin unavailable 1
3. If MRSA suspected (treatment failure, known local prevalence): Switch to clindamycin 20 mg/kg/day divided into 3 doses 1

Important Caveats

• Penicillin allergy: If immediate hypersensitivity, avoid both agents; use clindamycin or erythromycin instead 1
• Local resistance patterns: In areas with high beta-lactamase-producing S. aureus, co-amoxiclav may be reconsidered, though cephalexin typically maintains activity 2
• Treatment duration: Complete the full 10-day course regardless of early improvement to prevent resistance development 4
• MRSA emergence: If no improvement within 3–5 days, consider community-acquired MRSA and switch to MRSA-active agents 5, 6

The evidence consistently demonstrates cephalexin's superior efficacy with zero treatment failures in head-to-head comparison, making it the optimal first-line oral agent for pediatric impetigo when systemic therapy is indicated.